FGF4, fibroblast growth factor 4, 2249

N. diseases: 86; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0008497
Disease: Choriocarcinoma
Choriocarcinoma 		0.010 Biomarker disease BEFREE All cases of embryonal carcinoma (14 cases), yolk sac tumor (3 cases), and choriocarcinoma (3 cases) showed positive immunostaining for FGF8, FGF4, and FGFR1. 11764380 2001
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.040 AlteredExpression phenotype BEFREE Although hst-1 and int-2 are usually not expressed despite amplification, elevated transcription of the cyclin D gene is accompanied by its amplification, suggesting a role of a G1 cyclin in oesophageal carcinogenesis. 8095412 1993
CUI: C0001430
Disease: Adenoma
Adenoma 		0.010 GeneticVariation group BEFREE Although hst gene rearrangements and deletions of 11q13 are not associated with sporadic PRL-cell adenoma formation, a single patient was detected with a partial loss of chromosome 11, including the putative MEN-1 site. 8100831 1993
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.600 Biomarker disease BEFREE Although evaluation of the clinical significance of HST amplification and expression must await long-term follow-up of the patients, we suggest that HST gene product could play a role in development and/or progression of human breast cancer. 2474139 1989
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.560 Biomarker disease BEFREE Although evaluation of the clinical significance of HST amplification and expression must await long-term follow-up of the patients, we suggest that HST gene product could play a role in development and/or progression of human breast cancer. 2474139 1989
CUI: C0153685
Disease: Secondary malignant neoplasm of kidney
Secondary malignant neoplasm of kidney 		0.010 GeneticVariation disease BEFREE Although rearrangement of the gene was not detected in any of these samples, amplification of the hst-1 gene was found in 4 samples of tumors, including an invasive bladder cancer, both primary esophageal cancer and its lymph node metastasis, and kidney metastasis of an esophageal cancer. 3133332 1988
CUI: C0279626
Disease: Squamous cell carcinoma of esophagus
Squamous cell carcinoma of esophagus 		0.040 GeneticVariation disease BEFREE Amplification of 11q13.3 (FGF4) and deletion of 9p21.3 (CDKN2A) were found to be recurrent in all 38 superficial ESCCs analyzed. 27974698 2017
CUI: C0042769
Disease: Virus Diseases
Virus Diseases 		0.010 Biomarker group BEFREE Amplification of Int-2 was detectable (7 of 9 cases) in 78% of the HPV-positive carcinomas, whereas no virus infection could be found in the five cases with amplified Hst-1 only. 11016685 2000
CUI: C0546837
Disease: Malignant neoplasm of esophagus
Malignant neoplasm of esophagus 		0.020 GeneticVariation disease BEFREE Amplification of the hst-1 and int-2 genes on chromosome 11q13 has previously been found in over 20% of human primary esophageal cancers. 1533816 1992
CUI: C0007097
Disease: Carcinoma
Carcinoma 		0.060 AlteredExpression group BEFREE Amplification of the hst-1 gene in human esophageal carcinomas. 3136110 1988
CUI: C0010278
Disease: Craniosynostosis
Craniosynostosis 		0.020 GeneticVariation disease BEFREE An 11q11-q13.3 duplication, including FGF3 and FGF4 genes, in a patient with syndromic multiple craniosynostoses. 17632770 2007
CUI: C0340288
Disease: Stable angina
Stable angina 		0.020 Biomarker disease BEFREE Based on promising preclinical animal data, a series of four randomized placebo-controlled clinical trials have been conducted to determine the safety and efficacy of local delivery of fibroblast growth factor 4 with the use of adenovirus-vector-mediated gene transfer to induce myocardial angio-/arteriogenesis in patients with stable angina. 18555186 2008
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.600 Biomarker disease BEFREE BCL1 and two proto-oncogenes, INT2 and HST, were previously found to be coamplified in approximately 1/5 breast carcinomas. 2071147 1991
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.600 Biomarker disease BEFREE Because HST is described as an endogenous pan-HER inhibitor, the presence of this protein in breast carcinomas may portent the inefficiency of exogenous efforts to block HER2 dimerization, whereas its absence may justify such interventions. 18592003 2008
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE Case 1: A patient with locally unresectable HCC showed significant response induced by sorafenib, which allowed complete surgical resection.This tumor tested positive for FGF4. 29277815 2018
CUI: C0010278
Disease: Craniosynostosis
Craniosynostosis 		0.020 GeneticVariation disease BEFREE Clinical comparison of our patient with those previously reported with overlapping 11q duplications allows us to define the minimal duplicated region associated with craniosynostosis and strongly supports the hypothesis that the constitutional increased dosage of the FGF3 and FGF4 genes is a risk factor for craniosynostosis in humans. 24120895 2014
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.340 GeneticVariation disease BEFREE Co-amplification of integrated hepatitis B virus DNA and transforming gene hst-1 in a hepatocellular carcinoma. 2856253 1988
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE Coamplification of GST pi, HSTF1 and INT2 was observed in five tumors, and coamplification of GST pi and HSTF1 without amplification of INT2 in another tumor. 1826346 1991
CUI: C0152018
Disease: Esophageal carcinoma
Esophageal carcinoma 		0.040 Biomarker disease BEFREE Coamplification of the hst-1 and c-erbB-1 gene was found in one case of esophageal carcinoma. 3136110 1988
CUI: C0007097
Disease: Carcinoma
Carcinoma 		0.060 GeneticVariation group BEFREE Concerning band q13: (i) 50 tumors (approximately 17%) were co-amplified for BCL-1, HST & INT-2; (ii) in 3 cases, amplification extended to the SEA gene; (iii) in 6 carcinomas, BCL-1 was the only amplified marker. 2181375 1990
CUI: C0238198
Disease: Gastrointestinal Stromal Tumors
Gastrointestinal Stromal Tumors 		0.020 AlteredExpression group BEFREE CRISPR-mediated excision of the corresponding CTCF motifs in an SDH-intact GIST model disrupted the boundary between enhancer and oncogene, and strongly upregulated FGF4 expression. 31666694 2019
CUI: C0206664
Disease: Teratocarcinoma
Teratocarcinoma 		0.010 AlteredExpression disease BEFREE Differentiation associated modulation of K-FGF expression in a human teratocarcinoma cell line and in primary germ cell tumours. 2009969 1991
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.600 Biomarker disease CTD_human Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. 21936542 2011
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.560 Biomarker disease CTD_human Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. 21936542 2011
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms 		0.330 Biomarker group CTD_human Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. 21936542 2011